Mulberry leaf extract lowers postprandial blood glucose
Mulberry leaf extract (MLE) significantly reduces postprandial blood glucose and is safe at doses of up to 3 grams per day, a new randomized placebo-controlled pilot study shows.
After the 3-month study duration, postprandial self-monitoring blood glucose (SMBG) significantly decreased from baseline in participants who received MLE (n=12; 16.1 percent; p<0.05).
The improvement in postprandial SMBG in the MLE group was also significantly greater when compared with the placebo group (n=12; 18.2 percent; p<0.05).
While baseline systolic (SBP) and diastolic (DBP) blood pressures were significantly greater in the placebo group (150.1±11.60 and 81.4±9.6, respectively) than in the MLE group (130.8±15.38 and 72.2±10.6, respectively; p=0.002 and p=0.035, respectively), there were no significant differences between the two groups at 3 months (p=0.37 and p=0.82, respectively).
Similarly, there were no significant differences in baseline (p=0.13) and 3-month (p=0.44) haemoglobin A1C between the placebo and MLE groups.
There was no significant difference in the incidence of severe or symptomatic hypoglycaemia between the two groups (p=0.36). Two major adverse events were documented in the placebo group. MLE was not shown to be detrimental to body weight, blood pressure or serum marker levels.
The study included 24 patients with controlled type 2 diabetes mellitus and on mono- or oral combination therapy. Exclusion criteria included a history of cardiovascular disease, noncompliance with medication and insulin or alpha-glucosidase inhibitor medication.
There were three phases: a 2-week placebo run-in period, randomization and administration of placebos or MLE, and follow-up at 2 months to assess safety and A1C concentrations. Study outcomes included changes in A1C, pre- and postprandial SMBG and body weight.